Diabetes Type 2

 
Empagliflozin FDA-approved for Heart Failure with Reduced Ejection Fraction
August 19, 2021

The new indication for empagliflozin is to reduce risk of CV death and hospitalization for heart failure in patients with HFrEF,

High-deductible Health Plans May Negatively Impact Patients with Diabetes, New Review Suggests
August 13, 2021

Low-income patients with diabetes enrolled in high-deductible health plans used less preventive and primary care services and more emergency visits, suggests new review.

8 Questions on Diabetes Drugs for Cardioprotection
August 11, 2021

Take this quick quiz to test your knowledge of key findings in recent studies on the cardioprotective effects of SGLT2i and GLP-1 RAs.

Diabetes Drugs and Cardioprotection: A Summary for Primary Care
August 04, 2021

These concise summaries highlight the latest findings on the cardioprotective effects of SGLT2 inhibitors and GLP-1 RA in patients with diabetes.

In Patients with Uncontrolled T2D, Bariatric Surgery Associated with Long-term Improvement in Physical Domains, Diabetes-related QoL
July 29, 2021

Five years after bariatric surgery for uncontrolled T2D patients reported improvements in physical health and QoL but measures of psychosocial wellbeing remained flat.

Improved Outcomes Seen with Regular Antidepressant Use in Patients with Diabetes and Depression
July 26, 2021

Antidepressant therapy, used as prescribed, reduced risk for advanced complications of diabetes and death among more than 36 000 patients with comorbid diabetes and depression.

Achieving A1c Levels Below 7% Early May be Predictive of Long-term Glycemic Control in Patients with T2D
July 16, 2021

Early attainment of an A1c level below 7% was predictive of long-term glycemic control in patients with type 2 diabetes starting second-line glucose-lowering therapy in a new analysis.

Finerenone Approved as First-in-Class Treatment for Chronic Kidney Disease Associated with Type 2 Diabetes
July 12, 2021

The first nonsteroidal mineralocorticoid receptor antagonist to be approved for adults with T2D-associated CKD fills a significant treatment void for millions of patients.

Study: Statins Reduce CVD, Mortality in Low-risk Patients with Type 2 Diabetes
July 09, 2021

A recent study found that the use of statins in patients with newly diagnosed T2D reduced incidence of cardiovascular disease and death, particularly among older patients.

SGLT2 Inhibitors: 4 Questions Go Back to Basics
July 08, 2021

The SGLT-2 inhibitor class, originally approved as antihyperglycemic agents for T2D, has proven "pluripotent," adding indications for related conditions. Test your knowledge of a few basic facts.